William Bensinger, MD

Professor, Medicine, Oncology
University of Washington School of Medicine
Director, Autologous Bone Marrow Transplant Program
Seattle Cancer Care Alliance


Northwestern University, 1973, MD

Research Focus:

  • Autologous transplant
  • Targeted radiotherapy studies
  • Immunotherapy studies
  • Novel drug therapies

Clinical Expertise:

  • Autologous transplant
  • Multiple myeloma

Current Studies:

Examination of Novel Targeted Therapies and Identification of New Therapeutic Targets in Patients with Multiple Myeloma

A Study of Autologous Transplantation for patients with Multiple Myeloma Comparing Melphalan 280 mg/m2 + amifostine with melphalan 200 mg/m2 + amifostine, followed by further dose intensification and maintenance therapy

A Phase II study of lenalidomide following allogeneic stem cell transplant for multiple myeloma patients who relapse or have disease progression

Phase II Multicenter Dose Escalation Study of Carfilzomib with Pomalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma

A Phase III, Randomized, Open-Label, 3-Arm Study To Determine The Efficacy And Safety Of Lenalidomide (Revlimid) Plus Low-Dose Dexamethasone When Given Until Progressive Disease Or For 18 Four-Week Cycles Versus The Combination Of Melphalan, Prednisone, And Thalidomide Given For 12 Six-Week Cycles In Patients With Previously Untreated Multiple Myeloma Who Are Either 65 Years Of Age Or Older Or Not Candidates For Stem Cell Transplantation

An open label, dose escalation, phase 1 study evaluating the safety and tolerability of weekly dosing of the oral form of MLN9708, a second generation proteasome inhibitor, in adult patients with relapsed and refractory multiple myeloma

A Phase 1/2 study of ARRY-520 in patients with relapsed or refractory multiple myeloma

A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma

A Phase I Study of 90Y-BC8 monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone with or without Elotuzumab in Subjects with Previously Untreated Multiple Myeloma

A Phase 1, Open-Label, Multicenter Study of ACY-1215 in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma

A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone Prior to Autologous Stem Cell Transplant in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma

A Multicenter Phase 2 Study of the Bruton’s Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed or Refractory Multiple Myeloma, Mantle Cell Lymphoma or Diffuse Large B Cell Lymphoma

Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

A Phase 1 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hematological Malignancies

William Bensinger, MD

Contact Information

(206) 667-4933
(206) 667-4937
Additional contact

Mail Stop: D5-390